Neuphoria Therapeutics
NEUP
$4.27 0.00%
Exchange: NASDAQ | Sector: Healthcare | Industry: Medical Pharmaceuticals
Q3 2023
Published: Mar 31, 2024

Earnings Highlights

  • EPS of $-0.02 increased by 0% from previous year
  • Net income of -2.78M
  • "N/A" - N/A
NEUP
Company NEUP

Executive Summary

Neuphoria Therapeutics reported a modest quarterly revenue of $0.1657 million in QQ3 2023, accompanied by a substantial R&D program and operating costs. The quarter shows a narrowing of losses QoQ as SG&A expenses and overall operating expenditures declined sharply versus Q2 2023, while R&D remained elevated as the company advances its clinical pipeline. The resulting EBITDA of -$2.60 million and net loss of -$2.78 million reflect a typical pre-revenue, clinical-stage biotech profile, where near-term value creation hinges on pipeline milestones and successful capital formation. Absent a formal revenue stream or disclosed guidance, the primary investor considerations are pipeline progress, funding runway, and management’s ability to translate research into commercial value.

Key Performance Indicators

Operating Income
Stable
-2.39M
QoQ: N/A | YoY: N/A
Net Income
Stable
-2.78M
QoQ: N/A | YoY: N/A
EPS
Stable
-0.02
QoQ: N/A | YoY: N/A

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q1 2026 0.00 -4.41 +0.0% View
Q3 2024 15.00 0.05 +0.0% View
Q2 2024 0.66 -0.01 +0.0% View
Q1 2024 0.00 0.00 +0.0% View
Q3 2023 0.00 -0.02 +0.0% View